Na Li

Na Li, MD, PhD

  • Gastroenterology
  • Hepatology
  • Physician

Insurances We Accept

614-293-6255

About Me

As a gastroenterologist and hepatologist at The Ohio State University Wexner Medical Center, I see patients in clinic and perform endoscopic procedures. I enjoy working at OSU because it provides comprehensive support for patient care and a robust research environment. This makes it possible for me to provide the most appropriate and individualized care to my patients. In addition, patients also have the opportunity to receive the latest treatments through clinical trials.

My clinical focus is Non-Alcoholic Fatty Liver Disease (NAFLD), which affects about one-quarter of people worldwide. Patients with obesity and type 2 diabetes are at particularly high risk for disease progression (NASH), which often leads to poor health outcomes. Therefore, it is important to raise public awareness of NAFLD and intervene at early stages of the disease. Optimized care for patients with NAFLD requires teamwork among multi-specialty physicians, medical counselors, patients, and their family members. I feel fortunate to be a part of this team and happy to make such a positive impact on my patients’ lives.

When I am not working, I enjoy spending time with family, dancing, and traveling.

Learn more about receiving a tailored approach to treating fatty liver disease at the Ohio State Wexner Medical Center: https://wexnermedical.osu.edu/liver-diseases/fatty-liver-disease
Highlights
  • CURRENTLY AVAILABLE CLINICAL TRIALS ON NAFLD AS A PRINCIPLE INVESTIGATOR
  • ESSENCE study - The effect of semaglutide in subjects with non-cirrhotic NASH (phase 3). Status: actively enrolling.
  • Study by Galectin - A seamless, adaptive, phase 2b/3, double-blind, randomized, placebo-controlled, multicenter, international study evaluating the efficacy and safety of belapectin for the prevention of esophageal varices in NASH cirrhosis. Status: actively enrolling.
  • REVERSE study - A phase 3, double-blind, randomized, placebo-controlled, multicenter study to evaluate the efficacy and safety of obeticholic acid in subjects with compensated cirrhosis due to non-alcoholic steatohepatitis (NASH). Status: completed enrollment.
  • AURORA study - A phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate efficacy and safety of cenicriviroc for the treatment of liver fibrosis in adults with NASH. Status: early termination (due to lack of significant benefits).
  • For more information on these clinical trials, contact Anitha Guduri (Anitha.guduri@osumc.edu) or Gabrielle Volk (gabrielle.volk@osumc.edu).
Additional Languages I Speak
  • Mandarin

Procedures and Conditions I Treat

  • Hepatitis, Viral, Human
  • Gastroesophageal Reflux
  • Irritable Bowel Syndrome
  • Inflammatory Bowel Diseases
  • Liver Diseases
  • Endoscopy, Gastrointestinal
  • Capsule Endoscopy
  • Gastrointestinal Hemorrhage
  • Constipation
  • Digestive System Diseases
  • Fatty Liver
  • Neurosecretory Systems
  • Hepatitis
  • Liver Cirrhosis
  • Colonoscopy
  • Diarrhea
  • Gastroenteritis
  • Peptic Ulcer
  • Celiac Disease
  • Gastroscopy

Locations Where I Practice

Please note: Not all physicians schedule patients at each listed location. Please call the “Schedule an appointment” number shown above for scheduling assistance.

My Videos

Education and Training

Education History

Medical School

Xian Medical University, Xian, Shaanxi 710061,
MD
9/1/1993 - 7/31/1998

Graduate Program

University of Louisville School of Medicine, Louisville, KY
Ph.D.
8/20/2001 - 8/5/2005

Post Doctoral Fellow

University of Louisville Hospital, Louisville, KY

9/1/2005 - 6/1/2007

Internship

Long Island Jewish Medical Center, New Hyde Park, NY

7/1/2007 - 6/30/2008

Residency

Long Island Jewish Medical Center, New Hyde Park, NY

7/1/2008 - 6/30/2010

Fellowship

Long Island Jewish Medical Center, New Hyde Park, NY

7/1/2010 - 6/30/2013

Board Certifications

American Board of Internal Medicine
8/9/2010

American Board of Internal Medicine
12/31/2020

American Board of Internal Medicine (Subspecialty: Gastroenterology)
4/1/2022

Academic Information

My Department

Internal Medicine

My Division

Gastroenterology, Hepatology and Nutrition

Consulting and Related Relationships

At The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the University requires annual disclosures from all faculty members with external interests related to their University responsibilities.

As of 11/01/2020, Dr. Li has reported no relationships with companies or entities.